Visual performance in patients with neovascular age-related macular degeneration undergoing treatment with intravitreal ranibizumab

Journal of Ophthalmology

Volumn 2013, Issue , 2013, Pages

  Sabour Pickett, Sarah ^a,b,c   Loughman, James ^a,d   Nolan, John M ^b,c   Stack, Jim ^c   Pesudovs, Konrad ^e   Meagher, Katherine A ^c   Beatty, Stephen ^b,c  

^a DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

^b Institute of Vision Research   (Ireland)

^c Ireland   (Ireland)

^d University of KwaZulu Natal Faculty of Health Sciences   (South Africa)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884258752     PISSN: 2090004X     EISSN: 20900058     Source Type: Journal    
DOI: 10.1155/2013/268438     Document Type: Article

References (42)

1. Bhutto I. A., McLeod D. S., Hasegawa T., Kim S. Y., Merges C., Tong P., Lutty G. A., Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Experimental Eye Research 2006 82 1 99 110 2-s2.0-30344447284 10.1016/j.exer.2005.05.007
2. Wong T., Chakravarthy U., Klein R., Mitchell P., Zlateva G., Buggage R., Fahrbach K., Probst C., Sledge I., The Natural History and Prognosis of Neovascular age-related macular degeneration. A Systematic Review of the Literature and Meta-analysis. Ophthalmology 2008 115 1 116.e1 126.e1 2-s2.0-37449010146 10.1016/j.ophtha.2007.03.008
3. Frank R. N., Amin R. H., Eliott D., Puklin J. E., Abrams G. W., Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. American Journal of Ophthalmology 1996 122 3 393 403 2-s2.0-0029758823
4. Kvanta A., Algvere P. V., Berglin L., Seregard S., Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Investigative Ophthalmology and Visual Science 1996 37 9 1929 1934 2-s2.0-0029831672
5. Rosenfeld P. J., Brown D. M., Heier J. S., Boyer D. S., Kaiser P. K., Chung C. Y., Kim R. Y., Ranibizumab for neovascular age-related macular degeneration. The New England Journal of Medicine 2006 355 14 1419 1431 2-s2.0-33749445317 10.1056/NEJMoa054481
6. Brown D. M., Kaiser P. K., Michels M., Soubrane G., Heier J. S., Kim R. Y., Sy J. P., Schneider S., Ranibizumab versus verteporfin for neovascular age-related macular degeneration. The New England Journal of Medicine 2006 355 14 1432 1444 2-s2.0-33749451356 10.1056/NEJMoa062655
7. Owsley C., Contrast sensitivity. Ophthalmology Clinics of North America 2003 16 2 171 177 2-s2.0-0037946786 10.1016/S0896-1549(03)00003-8
8. Rubin G. S., Bandeen-Roche K., Huang G. H., Muñoz B., Schein O. D., Fried L. P., West S. K., The association of multiple visual impairments with self-reported visual disability: SEE project. Investigative Ophthalmology and Visual Science 2001 42 1 64 72 2-s2.0-0035174795
9. Koch K. R., Muether P. S., Hermann M. M., Hoerster R., Kirchhof B., Fauser S., Subjective perception versus objective outcome after intravitreal ranibizumab for exudative AMD. Graefe's Archive for Clinical and Experimental Ophthalmology 2012 250 201 209
10. Feigl B., Greaves A., Brown B., Functional outcomes after multiple treatments with ranibizumab in neovascular age-related macular degeneration beyond visual acuity. Journal of Clinical Ophthalmology 2007 1 167 175
11. Loshin D. S., White J., Contrast sensitivity. The visual rehabilitation of the patient with macular degeneration. Archives of Ophthalmology 1984 102 9 1303 1306 2-s2.0-0021153682
12. Sandberg M. A., Gaudio A. R., Slow photostress recovery and disease severity in age-related macular degeneration. Retina 1995 15 5 407 412 2-s2.0-0028881870
13. Parravano M., Oddone F., Tedeschi M., Chiaravalloti A., Perillo L., Boccassini B., Varano M., Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab: 24-month results. Retina 2010 30 7 1017 1024 2-s2.0-77954756852 10.1097/IAE.0b013e3181cfd3c6
14. Kiss C. G., Geitzenauer W., Simader C., Gregori G., Schmidt-Erfurth U., Evaluation of ranibizumab-induced changes in high- resolution optical coherence tomographic retinal morphology and their impact on visual function. Investigative Ophthalmology and Visual Science 2009 50 5 2376 2383 2-s2.0-65549147695 10.1167/iovs.08-2017
15. Midena E., Radin P. P., Pilotto E., Ghirlando A., Convento E., Varano M., Fixation pattern and macular sensitivity in eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. A Microperimetry Study. Seminars in Ophthalmology 2004 19 1-2 55 61 2-s2.0-10644231018 10.1080/08820530490882896
16. Ozdemir H., Karacorlu M., Senturk F., Karacorlu S. A., Uysal O., Microperimetric changes after intravitreal bevacizumab injection for exudative age-related macular degeneration. Acta Ophthalmologica 2012 90 71 75
17. Das R., Shi Y., Silvestri G., Chakravarthy U., Distortion maps from preferential hyperacuity perimetry are helpful in monitoring functional response to lucentis therapy. Retina 2009 29 7 1013 1018 2-s2.0-68249098931 10.1097/IAE.0b013e3181a91dbf
18. Ergun E., Maár N., Radner W., Barbazetto I., Schmidt-Erfurth U., Stur M., Scotoma size and reading speed in patients with subfoveal occult choroidal neovascularization in age-related macular degeneration. Ophthalmology 2003 110 1 65 69 2-s2.0-0037224688 10.1016/S0161-6420(02)01566-X
19. Stifter E., Weghaupt H., Benesch T., Thaler A., Radner W., Discriminative power of reading tests to differentiate visual impairment caused by cataract and age-related macular degeneration. Journal of Cataract and Refractive Surgery 2005 31 11 2111 2119 2-s2.0-30444431589 10.1016/j.jcrs.2005.03.080
20. Kloos P., Bernasconi P., Estermann S., Bachmann B., Rutishauser Y., Thölen A., Visual acuity and magnification requirement after ranibizumab in patients with wet age-related macular degeneration. Klinische Monatsblatter fur Augenheilkunde 2008 225 5 385 391 2-s2.0-47649086335 10.1055/s-2008-1027252
21. Chang T. S., Bressler N. M., Fine J. T., Dolan C. M., Ward J., Klesert T. R., Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology 2007 125 11 1460 1469 2-s2.0-36148980784 10.1001/archopht.125.11.1460
22. Suńer I. J., Kokame G. T., Yu E., Ward J., Dolan C., Bressler N. M., Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Investigative Ophthalmology and Visual Science 2009 50 8 3629 3635 2-s2.0-68349113753 10.1167/iovs.08-3225
23. Lamoureux E. L., Mitchell P., Rees G., Cheung G., Yeo I., Lee S. Y., Liu E., Wong T. Y., Impact of early and late age-related macular degeneration on vision-specific functioning. British Journal of Ophthalmology 2011 95 666 670
24. Singh R. P., Fu E. X., Smith S. D., Williams D. R., Kaiser P. K., Predictive factors of visual and anatomical outcome after intravitreal bevacizumab treatment of neovascular age-related macular degeneration: an optical coherence tomography study. British Journal of Ophthalmology 2009 93 10 1353 1358 2-s2.0-70349972787 10.1136/bjo.2008.141879
25. Kaiser P. K., Brown D. M., Zhang K., Hudson H. L., Holz F. G., Shapiro H., Schneider S., Acharya N. R., Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. American Journal of Ophthalmology 2007 144 6 850.e4 857.e4 2-s2.0-36249002808 10.1016/j.ajo.2007.08.012
26. Lalwani G. A., Rosenfeld P. J., Fung A. E., Dubovy S. R., Michels S., Feuer W., Davis J. L., Flynn H. W., Esquiabro M., A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. American Journal of Ophthalmology 2009 148 1 43 58 2-s2.0-67149101784 10.1016/j.ajo.2009.01.024
27. Hohberger B., Laemmer R., Adler W., Juenemann A. G. M., Horn F. K., Measuring contrast sensitivity in normal subjects with OPTEC 6500: influence of age and glare. Graefe's Archive for Clinical and Experimental Ophthalmology 2007 245 12 1805 1814 2-s2.0-36348950172 10.1007/s00417-007-0662-x
28. Rohrschneider K., Springer C., Bültmann S., Völcker H. E., Microperimetry-comparison between the micro perimeter 1 and scanning laser ophthalmoscope-fundus perimetry. American Journal of Ophthalmology 2005 139 1 125 134 2-s2.0-11844285720 10.1016/j.ajo.2004.08.060
29. Stifter E., König F., Lang T., Bauer P., Richter-Müksch S., Velikay-Parel M., Radner W., Reliability of a standardized reading chart system: variance component analysis, test-retest and inter-chart reliability. Graefe's Archive for Clinical and Experimental Ophthalmology 2004 242 1 31 39 2-s2.0-10744220488 10.1007/s00417-003-0776-8
30. Massin P., Vicaut E., Haouchine B., Erginay A., Paques M., Gaudric A., Reproducibility of retinal mapping using optical coherence tomography. Archives of Ophthalmology 2001 119 8 1135 1142 2-s2.0-0034900136
31. Loughman J., Akkali M. C., Beatty S., Scanlon G., Davison P. A., O'Dwyer V., Cantwell T., Major P., Stack J., Nolan J. M., The relationship between macular pigment and visual performance. Vision Research 2010 50 13 1249 1256 2-s2.0-77953139154 10.1016/j.visres.2010.04.009
32. Brown D. M., Michels M., Kaiser P. K., Heier J. S., Sy J. P., Ianchulev T., Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study. Ophthalmology 2009 116 1 57 65 2-s2.0-57949094834 10.1016/j.ophtha.2008.10.018
33. Fung A. E., Lalwani G. A., Rosenfeld P. J., Dubovy S. R., Michels S., Feuer W. J., Puliafito C. A., Davis J. L., Flynn H. W., Esquiabro M., An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. American Journal of Ophthalmology 2007 143 4 566 583 2-s2.0-33947403618 10.1016/j.ajo.2007.01.028
34. Kaiser P. K., Blodi B. A., Shapiro H., Acharya N. R., Angiographic and optical coherence tomographic results of the MARINA Study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007 114 10 1868 1875 2-s2.0-34748844162 10.1016/j.ophtha.2007.04.030
35. Williams T. A., Blyth C. P., Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12. Eye 2011 25 1617 1621
36. Monés J., Rubin G. S., Contrast sensitivity as an outcome measure in patients with subfoveal choroidal neovascularisation due to age-related macular degeneration. Eye 2005 19 11 1142 1150 2-s2.0-31044453580 10.1038/sj.eye.6701717
37. Scott I. U., Feuer W. J., Jacko J. A., Impact of visual function on computer task accuracy and reaction time in a cohort of patients with age-related macular degeneration. American Journal of Ophthalmology 2002 133 3 350 357 2-s2.0-0036176536 10.1016/S0002-9394(01)01406-4
38. Rubin G. S., Roche K. B., Prasada-Rao P., Fried L. P., Visual impairment and disability in older adults. Optometry and Vision Science 1994 71 12 750 760 2-s2.0-0028560320 10.1097/00006324-199412000-00005
39. Kuyk T., Elliott J. L., Visual factors and mobility in persons with age-related macular degeneration. Journal of Rehabilitation Research and Development 1999 36 4 303 312 2-s2.0-0033233134
40. Varano M., Scassa C., Scanning laser ophthalmoscope microperimetry. Seminars in Ophthalmology 1998 13 4 203 209 2-s2.0-0032424045
41. Alexander P., Mushtaq F., Osmond C., Amoaku W., Microperimetric changes in neovascular age-related macular degeneration treated with ranibizumab. Eye 2012 26 678 683
42. Frennesson C., Nilsson U. L., Peebo B. B., Nilsson S. E. G., Significant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degeneration. Acta Ophthalmologica 2010 88 4 420 425 2-s2.0-77952910606 10.1111/j.1755-3768.2009.01576.x